Guide

Valuing science-driven companies is one of the hardest challenges in corporate finance. Whether a business is preclinical, commercialising, scaling, or preparing for a transaction, traditional metrics often fail to capture the true drivers of value: intellectual property, scientific progress, regulatory pathways, and multi-application technology platforms. At Sherwood, we work with companies across biotech, medtech, digital health, advanced manufacturing, AI, and deep tech to